Altogether, our results position BCOR mutations as a potential genomic biomarker that may help pave the way toward repurposing DHODH inhibitors and advancing precision medicine strategies in AML and other cancers; and we hope this preliminary study will stimulate deeper investigations into high-ROS cancers and the mechanisms underlying DHODH vulnerability. This evidence concerns the gene BCOR and acute myeloid leukemia.